Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Sajeve Thomas et al.|The Lancet|2024Cited by 729
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Nature Medicine|2023Cited by 208
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A. Cohen, Arjun Jeyarajah, Aime Powell et al.|Gynecologic Oncology|2019Cited by 121
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian CancerSarah P. Blagden, Hani Gabra, Anne Hamilton et al.|Clinical Cancer Research|2018Cited by 66
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)Georgina V. Long, John M. Kirkwood, Michele Del Vecchio et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 25